Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as a solution for the treatment of acute radiation syndrome. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.

Pluri Inc.

Pluri is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global wellbeing and sustainability. The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of initiatives— from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri’s method is uniquely accurate, scalable, cost-effective, and consistent from batch to batch. Pluri currently operates in the field of regenerative medicine and food-tech and aims to establish partnerships that leverage the company’s 3D cell-based technology to additional industries that require effective, mass cell production. To learn more, visit us at www.pluri-biotech.com or follow us on LinkedIn and Twitter.

Pluri

Today we begin a new chapter, full of hope and opportunity. 
Promoting wellbeing and sustainability and advancing solutions to humanity’s greatest challenges.
Creating a better tomorrow for all of us.
We are Pluri.
#pluri

🍁🦃 During these challenging times, we're thankful for our team, partners, community, and we remember the importance of family time, something that must be appreciated and can never be taken for granted.

Wishing everyone a safe and peaceful Thanksgiving from Everyone in the Pluri Family! !

#Thanksgiving2023 #happythanksgiving 🍂

#KitesForFreedom 🪁✨ This World Children's Day, Pluri is taking a stand for the 39 babies and children held hostage by Hamas. As these kites soar, let's collectively remember and call for the safe return of those who are taken and missing.

Share this initiative to spotlight the immeasurable value of every human life. Join us in saying #bringthemhomenow. 

#freeourkids_il #FREEOURKIDS_IL 

At Pluri, we're joining the "Empty Chair" initiative, set up by the families of the hostages, to demand the safe return of all hostages taken by Hamas. By placing yellow chairs at our entrances, symbolizing the empty spaces waiting to be filled in our homes and hearts, we honor those missing and strengthen the call for their return.

Join us in setting up an empty chair or spreading the word. Together, let’s show the world the value of every human life.

#BringThemHomeNow

https://lnkd.in/d-AtqAkS

#bringthemhome #standwithIsrael #hamasisISIS 

𝐖𝐞’𝐫𝐞 𝐨𝐧 𝐍𝐚𝐬𝐝𝐚𝐪! 🇮🇱💪
 
Israeli companies have been listed on Nasdaq for over 35 years, during which these companies and entrepreneurs have defined new industries, innovated new products, and changed the world for the better. 

With over 100 Israeli-listed companies on the Nasdaq and 7,500 startups, the Israeli tech ecosystem continues to show resilience, even in the face of adversities.

Our nation's technological prowess remains robust and unassailable, and businesses continue to serve and delight their global customers. 

As always – “Israeli tech delivers, 𝐧𝐨 𝐦𝐚𝐭𝐭𝐞𝐫 𝐰𝐡𝐚𝐭”.

Thanks Nasdaq for supporting our message.

#nomatterwhat 

COM:PLURI-BIOTECH

Pluri Biotech Ltd.

Last Close

4.85

22/11 21:00

Market Cap

30.92M

Beta: -

Volume Today

2.59K

Avg: -